Results 221 to 228 of about 19,665 (228)

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Expert Opinion on Biological Therapy, 2010
Nico M Wulffraat
exaly  

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations

Expert Review of Clinical Immunology, 2015
Andreas Woerner, Annette Von Scheven-Gete, Rolando Cimaz   +2 more
exaly  

The role of heme oxygenase-1 in systemic-onset juvenile idiopathic arthritis

Modern Rheumatology, 2009
Masaaki Mori, Shoko Nakajima, Tomoyuki Imagawa   +2 more
exaly  

Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis

Modern Rheumatology, 2019
Naomi Iwata, Masaki Shimizu, Shimizu Masaki   +2 more
exaly  

HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

Proceedings of the National Academy of Sciences of the United States of America, 2015
Ioanna Tachmazidou, Andrew S Zeft, Maria Odete E Hilario   +2 more
exaly  

Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab

Modern Rheumatology, 2012
Ryoki Hara, Tomoyuki Imagawa, Masaaki Mori   +2 more
exaly  

Anakinra for systemic juvenile idiopathic arthritis

Archives of Disease in Childhood, 2011
openaire   +1 more source

Pancreatitis in systemic juvenile idiopathic arthritis.

Clinical and experimental rheumatology, 2019
Ankita, Singh, Nameirakpam, Johnson, Gummadi, Anjani, Rakesh Kumar, Pilania, Vybhav, Venkatesh, Sadhna, Lal, Pandiarajan, Vignesh   +6 more
openaire   +1 more source